Hydrocortisone Acetate

證據等級: L5

預測適應症: 10 個

Hydrocortisone Acetate: From Corticosteroid Anti-Inflammatory Therapy to Alopecia Areata

One-Sentence Summary

Hydrocortisone acetate is a corticosteroid; the evidence pack does not document its original approved indication (no New Zealand licenses or original_indications data are recorded), but corticosteroids as a class are established anti-inflammatory/immunosuppressive agents. The TxGNN model predicts it may be effective for Alopecia Areata, supported by 1 completed Phase 3 clinical trial and 2 supporting publications — already reflecting existing clinical practice (topical/intralesional corticosteroid use) rather than a novel hypothesis.

Quick Overview

Item	Content
Original Indication	Not documented (no New Zealand licenses or original indication data available in the evidence pack)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.94%
Evidence Level	L2 (1 completed Phase 3 RCT involving the drug)
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for hydrocortisone acetate is not available in the evidence pack. Based on known pharmacology, hydrocortisone acetate belongs to the corticosteroid class, which acts through anti-inflammatory and local immunosuppressive effects — this is a well-characterized class mechanism, even though the specific documented MOA for this product is a data gap (flagged as High severity in the source data).

Because the original approved indication for this specific product is not documented, the relationship to alopecia areata cannot be assessed directly against a labeled indication. However, topical and intralesional corticosteroids — including hydrocortisone formulations — are already a standard, widely used treatment approach for alopecia areata in dermatology practice, which strengthens plausibility independent of the missing original-indication data.

Mechanistically, alopecia areata is driven by T-cell-mediated autoimmune attack on hair follicles. Corticosteroids suppress this local inflammatory/immune process, which is precisely why they are already used clinically (topical application, intralesional injection) for this condition. This makes the TxGNN prediction a reinforcement of established practice rather than a new mechanistic hypothesis. One caveat noted directly in the source rationale: this specific product (hydrocortisone acetate) is currently not marketed in New Zealand, so actual accessibility depends on confirming approved dosage forms and indication status.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01453686	Phase 3	Completed	41	Randomized controlled trial in children comparing clobetasol propionate 0.05% cream vs. hydrocortisone 1% cream for alopecia areata; addresses the lack of high-quality evidence on which topical steroid potency is safe and effective for this population.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
153470	1979	Review	MMW, Münchener medizinische Wochenschrift	Reviews advances in topical dermatologic therapy; notes hydrocortisone acetate's anti-inflammatory potency is comparable to newer topical corticosteroids, informing its continued use as a reference-standard topical steroid.
4755919	1973	Case series	Przegląd dermatologiczny	Describes treatment of severe alopecia areata using intralesional subcutaneous injections of hydrocortisone acetate suspension.

New Zealand Market Information

This product currently has no authorized license or marketed product in New Zealand (0 authorizations on record).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

One completed Phase 3 RCT directly involving hydrocortisone in alopecia areata, together with established clinical use of topical/intralesional corticosteroids for this condition, supports cautious advancement — but the drug's unmarketed status in New Zealand and missing MOA/safety data mean it cannot proceed without further verification. (Note: 9 additional lower-ranked predicted indications for this drug — including telogen effluvium, alopecia mucinosa, and others — currently have no supporting trials or literature and remain at Hold.)

To proceed, the following is needed:

TFDA-equivalent package insert warnings and contraindications (currently a Blocking data gap; required before any safety pre-assessment)
Detailed mechanism of action data via DrugBank (currently a High-severity data gap)
Confirmation of New Zealand regulatory pathway and available dosage forms, given the product is currently unmarketed
Additional controlled trial data to strengthen evidence beyond a single Phase 3 study
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.